The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20251407: ACG Parent Holdings, LP; Arrow Management Holdings, LLC
20251412: TA XV-B, L.P.; HealthMark Holdings, LLC
20251413: Gridiron Capital Fund V, L.P.; Greenix Investments, LLC
20251414: Citation Fund I LP; GML Holdings L.L.C.
20251423: Sterling Infrastructure, Inc.; Ray Waddell
20251425: Enzon Pharmaceuticals, Inc.; Carl C. Icahn
20251429: Griffon Topco, LP; Layerzero Power Systems, Inc.
20251433: KKR Management LLP; Michael Marhofer
20251454: HEICO Corporation; Andrew M. Jackson
20251456: Hoshizaki Corporation; Mason Wells Buyout Fund IV, LP
Caremark Rx, Zinc Health Services, et al., In the Matter of (Insulin)
The FTC filed a lawsuit against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs.
NextMed
In July 2025, the Federal Trade Commission announced that the operators of telemedicine company Southern Health Solutions, Inc., doing business as Next Medical and NextMed, have agreed to settle the FTC’s charges that they used deceptive claims about costs and weight loss, fake reviews, and fake testimonials to lure consumers into buying their weight-loss membership programs that had hidden terms and conditions.
The proposed order requires NextMed and its principals to pay $150,000, which is expected to be used to provide refunds to consumers.
Roca Labs, Inc.
The FTC took action against the Florida-based marketers of a line of weight-loss supplements who allegedly made baseless claims for their products, and then threatened to enforce “gag clause” provisions against consumers to stop them from posting negative reviews and testimonials online. In September 2018, a federal district court ruled in the FTC’s favor, issuing a summary judgment against the defendants, and in July 2025 the Commission announced it was returning more than $409,000 to defrauded consumers.